Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons the GRAAL trial

Clinical Drug Investigation

Volumn 32, Issue 7, 2012, Pages 451-463

  Wessel, Franois ^a   Chartier, Antoine ^b   Meunier, Jean Pierre ^c   Magnan, Antoine ^a,d  

^a L INSTITUT DU THORAX   (France)

^b ALK Abellò France Medical Department   (France)

^c Axonal Biostatem   (France)

^d UNIVERSITÉ DE NANTES   (France)

Author keywords

Allergic rhinoconjunctivitis; grass pollen hypersensitivity; seasonal; sublingual

Indexed keywords

GRASS POLLEN VACCINE;

ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DESENSITIZATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FRANCE; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH EDEMA; MULTICENTER STUDY; OBSERVATIONAL STUDY; OCULAR PRURITUS; ORAL PARESTHESIA; ORAL PRURITUS; PATIENT COMPLIANCE; PHARYNX DISCOMFORT; PHASE 4 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHINITIS; SIDE EFFECT; SNEEZING; THROAT IRRITATION; TONGUE SWELLING;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; AGED; ALLERGENS; CHI-SQUARE DISTRIBUTION; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FRANCE; HUMANS; INTRADERMAL TESTS; LINEAR MODELS; MALE; MIDDLE AGED; PATIENT SAFETY; PLANT EXTRACTS; POACEAE; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC, SEASONAL; RISK ASSESSMENT; RISK FACTORS; SEASONS; TABLETS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862025657     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11634270-000000000-00000     Document Type: Article

References (31)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004 Nov; 24 (5): 758-64 (Pubitemid 39504428)
2. Klossek JM, Annesi-Maesano I, Pribil C. et al. INSTANT: national survey of allergic rhinitis in a French adult population based-sample [in French]. Presse Med 2009 Sep; 38 (9): 1220-9
3. Walker S, Khan-Wasti S, Fletcher M. et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: casecontrol study. J Allergy Clinical Immunol 2007 Aug; 120 (2): 381-7 (Pubitemid 47102376)
4. Canonica GW, Bousquet J, Mullol J. et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 Suppl. 85: 17-25 (Pubitemid 47561569)
5. Moller C, Dreborg S, Ferdousi HA. et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002 Feb; 109 (2): 251-6
6. Bousquet J, Khaltaev N, Cruz AA. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008 Apr; 63 (Suppl. 86): 8-160
7. WallaceDV, DykewiczMS, Bernstein DI. et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 2008 Aug; 122 Suppl. 2: S1-84 (Pubitemid 352033573)
8. Durham SR, Walker SM, Varga EM. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999 Aug 12; 341 (7): 468-75 (Pubitemid 29372886)
9. Novembre E, Galli E, Landi F. et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004 Oct; 114 (4): 851-7 (Pubitemid 39330257)
10. Des Roches A, Paradis L, Menardo JL. et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997 Apr; 99 (4): 450-3 (Pubitemid 27173080)
11. Inal A, Altintas DU, Yilmaz M. et al. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 2007; 17 (2): 85-91 (Pubitemid 46623709)
12. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003 Mar; 111 (3): 437-48, quiz 49 (Pubitemid 36337857)
13. Malling HJ, Lund L, Ipsen H. et al. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 2006; 16 (3): 162-8
14. Durham SR, Yang WH, Pedersen MR. et al. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 Apr; 117 (4): 802-9
15. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQstandardised grass allergen tablet for sublingual immunotherapy: A randomized, placebo-controlled trial. Allergy 2006 Feb; 61 (2): 181-4 (Pubitemid 43381827)
16. Calderon M, Essendrop M. Specific immunotherapy with high dose SO standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 2006; 16 (6): 338-44 (Pubitemid 44953951)
17. Dahl R, Kapp A, Colombo G. et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 Aug; 118 (2): 434-40 (Pubitemid 44160721)
18. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006 Feb; 61 (2): 185-90 (Pubitemid 43381828)
19. Calderon M, Brandt T. Treatment of grass pollen allergy: focus on a standardized grass allergen extract-Grazax(R). Ther Clin Risk Manag 2008 Dec; 4 (6): 1255-60
20. Magnan A, Wessel F, Meunier JP. et al. Safety of specific immunotherapy with tablets taken at home [in French]. Rev Fr Allergol 2010; 50: 7-14
21. ALK-Abello. Summary of Product Characteristics: GRAZAX 75,000 SQ-T oral lyophilisate Hørsholm, Denmark 2011
22. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline E2A, Step 5: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting 1994
23. Didier A, WormM, Horak F. et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 2011 Sep; 128 (3): 559-66
24. Dahl R, Kapp A, Colombo G. et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008 Feb; 121 (2): 512-8; e2
25. Durham SR, Emminger W, Kapp A. et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012 Mar; 129 (3): 717-25; e5
26. Durham SR, Emminger W, Kapp A. et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010 Jan; 125 (1): 131-8; e1-7
27. Gentile D, Skoner DP. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis. Curr Allergy Asthma Rep 2011 Apr; 11 (2): 131-8
28. Ciprandi G, Alesina R, Ariano R. et al. Characteristics of patients with allergic polysensitization: The POLISMAIL study. Eur Ann Allergy Clin Immunol 2008 Nov; 40 (3): 77-83
29. Magnan A, Meunier JP, Saugnac C. et al. Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: A French observational crosssectional study. Allergy 2008 Mar; 63 (3): 292-8 (Pubitemid 351224680)
30. Alesina R, Milani M, Pecora S. A multicenter, randomized, parallel-group trial assessing compliance, tolerability, safety, and efficacy to treatment with grass allergy tablets in 261 patients with grass pollen rhinoconjunctivitis. J Allergy (Cairo) 2012; 2012; 673502
31. Osterberg L, Blaschke T. Adherence to medication. New Engl J Med 2005 Aug 4; 353 (5): 487-97 (Pubitemid 41127293)